Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group
Abha A. Gupta, Wei Xue, Douglas J Harrison, Douglas S. Hawkins, Roshni Dasgupta, Suzanne Wolden, Barry Shulkin, Amira Qumseya, Jonathan C Routh, Tamara MacDonald, Shari L. Feinberg, Brian Crompton, Erin R. Rudzinski, Michael Arnold, Raj Venkatramani
Topics & Concepts
MedicineRhabdomyosarcomaTemsirolimusChemotherapyOncologyInternal medicinePediatricsSarcomaDiscovery and development of mTOR inhibitorsPathologyChemistryApoptosisBiochemistryProtein kinase BSarcoma Diagnosis and TreatmentFOXO transcription factor regulationGlioma Diagnosis and Treatment